Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insulin Pumps, Including Sensor-Augmented, Enter Competitive Bidding

This article was originally published in The Gray Sheet

Executive Summary

Now that insulin pumps are part of CMS’ competitive bidding program, there is a possibility of reimbursement reductions down the road. And in a separate process, CMS denied Medtronic’s request to establish a new HCPCS code for sensor-augmented insulin pumps.

You may also be interested in...



CMS Expands Competitive Bidding To Include Insulin Pumps, More CPAP Areas

The US Medicare agency will expand its competitive bidding program for durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) to include insulin pumps, and will add 10 new competitive bidding areas for continuous positive airway pressure (CPAP) devices. Many device suppliers, as well as Trump’s HHS Secretary-nominee Tom Price, oppose the bidding program.

CMS Proposes To Deny Most HCPCS Code Requests For DMEPOS Items

CMS met this week, and will again on June 3, to hear arguments in support of establishing new or revised level II HCPCS codes for 33 different durable medical equipment, prosthetics and orthotics items and medical supplies. But in preliminary rulings the agency signaled plans to deny all but two of the requests.

Survey Finds Competitive Bidding Restricts Access To Diabetes Products

The American Association of Diabetes Educators surveyed suppliers participating in the nationwide competitive bidding system for mail-ordered diabetes testing systems and found that they are not offering access to as many brands as they initially promised in their bids.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel